eligibility_summary
Eligible: adults 18–79 with relapsed/refractory B‑cell lymphoma (DLBCL incl CNS, MCL, FL 1–3a, marginal), ECOG 0–1 (2 if hematologic), adequate marrow, venous access for apheresis, ≥2‑mo life expectancy, consent. Exclude: candidates for curative options/CAR‑T, recent trial drug, other active cancer, early post‑allo‑HSCT or on immunosuppression, active infection/HIV/HBV/HCV, major organ dysfunction, pregnancy, no contraception, chronic steroids >10 mg, prior anti‑CD19 CAR‑T, hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: TranspoCART19, an autologous, gene-modified cellular therapy (CAR-T). Patient T cells are expanded and engineered using the non-viral Sleeping Beauty transposon system to express an anti-CD19 CAR with 4-1BB (costimulatory) and CD3ζ (activation) domains, plus huEGFRt as a selectable/safety tag. Mechanism: CAR engagement of CD19 on B cells activates T cells via CD3ζ, with 4-1BB enhancing proliferation, persistence, and survival, resulting in targeted cytotoxicity against malignant CD19+ B cells, huEGFRt enables tracking or antibody-mediated depletion if required. Targets: CD19-expressing B-cell lymphomas, T-cell activation (CD3ζ) and TNFRSF9/4-1BB costimulatory pathways. Trial: Phase I/IIa, single-arm, open-label in relapsed/refractory B-cell lymphoma.